Kimberly Jordan
Concepts (324)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 9 | 2026 | 595 | 1.500 |
Why?
| | Tumor Microenvironment | 12 | 2026 | 735 | 1.350 |
Why?
| | T-Lymphocytes | 11 | 2022 | 1997 | 1.110 |
Why?
| | Cancer Vaccines | 7 | 2021 | 162 | 1.100 |
Why?
| | Myeloid-Derived Suppressor Cells | 6 | 2026 | 76 | 1.100 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 7 | 2025 | 1969 | 0.820 |
Why?
| | Antigens, Neoplasm | 6 | 2021 | 271 | 0.730 |
Why?
| | Receptors, Antigen, T-Cell | 7 | 2021 | 673 | 0.670 |
Why?
| | Focal Adhesion Protein-Tyrosine Kinases | 1 | 2020 | 35 | 0.650 |
Why?
| | Baculoviridae | 3 | 2009 | 44 | 0.620 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2020 | 69 | 0.620 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 427 | 0.580 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2023 | 782 | 0.570 |
Why?
| | Insecta | 3 | 2009 | 71 | 0.550 |
Why?
| | Neoadjuvant Therapy | 2 | 2022 | 467 | 0.550 |
Why?
| | Extracellular Vesicles | 1 | 2020 | 171 | 0.540 |
Why?
| | Melanoma | 4 | 2023 | 761 | 0.500 |
Why?
| | Colorectal Neoplasms | 4 | 2025 | 868 | 0.500 |
Why?
| | Granulocytes | 1 | 2017 | 82 | 0.500 |
Why?
| | Pancreatic Cyst | 1 | 2017 | 50 | 0.480 |
Why?
| | Lymphocyte Activation | 4 | 2017 | 1133 | 0.470 |
Why?
| | Monocytes | 2 | 2020 | 539 | 0.440 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 3 | 2025 | 133 | 0.430 |
Why?
| | CD8-Positive T-Lymphocytes | 7 | 2024 | 923 | 0.430 |
Why?
| | Vaccines | 2 | 2010 | 389 | 0.430 |
Why?
| | Spleen | 1 | 2017 | 508 | 0.430 |
Why?
| | Cystadenocarcinoma, Serous | 2 | 2026 | 89 | 0.420 |
Why?
| | Xenograft Model Antitumor Assays | 8 | 2025 | 936 | 0.410 |
Why?
| | Programmed Cell Death 1 Receptor | 3 | 2022 | 266 | 0.410 |
Why?
| | Myeloid Cells | 2 | 2020 | 147 | 0.400 |
Why?
| | Neoplasms | 6 | 2017 | 2913 | 0.390 |
Why?
| | Vaccines, Subunit | 2 | 2012 | 53 | 0.390 |
Why?
| | Cell Line, Tumor | 11 | 2026 | 3551 | 0.380 |
Why?
| | Tomography, X-Ray Computed | 1 | 2023 | 2770 | 0.380 |
Why?
| | Histone-Lysine N-Methyltransferase | 2 | 2024 | 141 | 0.370 |
Why?
| | Mice, Inbred BALB C | 10 | 2026 | 1261 | 0.360 |
Why?
| | Complementarity Determining Regions | 1 | 2012 | 54 | 0.360 |
Why?
| | Mice | 26 | 2026 | 18357 | 0.340 |
Why?
| | Gamma Rays | 2 | 2021 | 57 | 0.320 |
Why?
| | Benzimidazoles | 2 | 2024 | 189 | 0.320 |
Why?
| | Antibodies, Monoclonal, Humanized | 4 | 2025 | 992 | 0.300 |
Why?
| | Antineoplastic Agents, Immunological | 4 | 2020 | 198 | 0.300 |
Why?
| | Inflammation | 1 | 2020 | 2883 | 0.290 |
Why?
| | CD47 Antigen | 2 | 2025 | 42 | 0.270 |
Why?
| | H-2 Antigens | 1 | 2008 | 111 | 0.260 |
Why?
| | Breast Neoplasms | 1 | 2020 | 2393 | 0.260 |
Why?
| | Female | 32 | 2026 | 79025 | 0.260 |
Why?
| | Immunotherapy | 5 | 2021 | 667 | 0.260 |
Why?
| | Pancreatic Neoplasms | 3 | 2021 | 928 | 0.260 |
Why?
| | Animals | 29 | 2026 | 38100 | 0.260 |
Why?
| | Cell Proliferation | 7 | 2024 | 2514 | 0.250 |
Why?
| | Antigens | 1 | 2009 | 348 | 0.250 |
Why?
| | Carcinoma, Pancreatic Ductal | 2 | 2021 | 293 | 0.250 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2025 | 883 | 0.250 |
Why?
| | Proteome | 2 | 2022 | 514 | 0.250 |
Why?
| | Peptide Library | 4 | 2013 | 91 | 0.240 |
Why?
| | Tumor Escape | 2 | 2017 | 49 | 0.240 |
Why?
| | Receptors, Interleukin-8B | 1 | 2026 | 29 | 0.240 |
Why?
| | Peptides | 4 | 2021 | 998 | 0.240 |
Why?
| | Survival Analysis | 4 | 2021 | 1378 | 0.240 |
Why?
| | Vaccination | 3 | 2010 | 1428 | 0.240 |
Why?
| | Disease Models, Animal | 6 | 2026 | 4569 | 0.230 |
Why?
| | Granuloma | 1 | 2026 | 97 | 0.230 |
Why?
| | Humans | 46 | 2026 | 145750 | 0.230 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 3 | 2021 | 153 | 0.230 |
Why?
| | Phthalazines | 1 | 2025 | 63 | 0.220 |
Why?
| | Transcriptome | 2 | 2022 | 1043 | 0.220 |
Why?
| | Lupus Nephritis | 1 | 2025 | 67 | 0.220 |
Why?
| | Lung Neoplasms | 3 | 2024 | 2667 | 0.220 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2025 | 108 | 0.220 |
Why?
| | Models, Biological | 2 | 2021 | 1764 | 0.220 |
Why?
| | Major Histocompatibility Complex | 4 | 2021 | 233 | 0.210 |
Why?
| | Tryptophan Oxygenase | 1 | 2024 | 33 | 0.200 |
Why?
| | Keratins | 1 | 2024 | 171 | 0.200 |
Why?
| | Bevacizumab | 1 | 2024 | 168 | 0.200 |
Why?
| | Interferons | 2 | 2022 | 186 | 0.200 |
Why?
| | beta Catenin | 1 | 2025 | 254 | 0.200 |
Why?
| | Signal-To-Noise Ratio | 1 | 2023 | 73 | 0.200 |
Why?
| | Neoplasms, Experimental | 2 | 2021 | 167 | 0.190 |
Why?
| | Piperazines | 1 | 2025 | 375 | 0.190 |
Why?
| | Tuberculosis | 1 | 2026 | 284 | 0.190 |
Why?
| | Disease Progression | 5 | 2026 | 2865 | 0.190 |
Why?
| | Mycobacterium tuberculosis | 1 | 2026 | 318 | 0.190 |
Why?
| | Fallopian Tubes | 1 | 2022 | 33 | 0.190 |
Why?
| | Artifacts | 1 | 2023 | 143 | 0.190 |
Why?
| | Prognosis | 5 | 2024 | 4329 | 0.190 |
Why?
| | Dendritic Cells | 4 | 2020 | 500 | 0.190 |
Why?
| | Macrophages | 3 | 2026 | 1507 | 0.190 |
Why?
| | Ephrin-B2 | 2 | 2021 | 45 | 0.180 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2024 | 122 | 0.180 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2022 | 1191 | 0.180 |
Why?
| | Fibrosis | 2 | 2024 | 561 | 0.180 |
Why?
| | Neoplasms, Second Primary | 1 | 2023 | 102 | 0.180 |
Why?
| | Tretinoin | 2 | 2023 | 125 | 0.170 |
Why?
| | Flow Cytometry | 5 | 2022 | 1165 | 0.170 |
Why?
| | Blood | 1 | 2022 | 107 | 0.170 |
Why?
| | Mycosis Fungoides | 1 | 2021 | 63 | 0.170 |
Why?
| | Gene Expression Profiling | 3 | 2021 | 1777 | 0.170 |
Why?
| | ADAM10 Protein | 1 | 2021 | 29 | 0.170 |
Why?
| | Middle Aged | 12 | 2025 | 36297 | 0.160 |
Why?
| | Ovary | 1 | 2022 | 234 | 0.160 |
Why?
| | Synovial Membrane | 1 | 2022 | 123 | 0.160 |
Why?
| | Precision Medicine | 1 | 2025 | 461 | 0.160 |
Why?
| | Seroconversion | 1 | 2021 | 48 | 0.160 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2021 | 78 | 0.160 |
Why?
| | Proteomics | 3 | 2024 | 1188 | 0.160 |
Why?
| | Oligonucleotides, Antisense | 1 | 2020 | 120 | 0.160 |
Why?
| | Databases, Genetic | 1 | 2021 | 238 | 0.160 |
Why?
| | Eosinophilic Esophagitis | 1 | 2024 | 332 | 0.160 |
Why?
| | Immunity | 1 | 2020 | 140 | 0.150 |
Why?
| | Splenectomy | 1 | 2020 | 61 | 0.150 |
Why?
| | Radiation Injuries | 1 | 2021 | 149 | 0.150 |
Why?
| | Diagnostic Imaging | 1 | 2022 | 337 | 0.150 |
Why?
| | Cell Adhesion | 1 | 2020 | 451 | 0.150 |
Why?
| | Case-Control Studies | 3 | 2022 | 3634 | 0.140 |
Why?
| | Receptor, EphB4 | 1 | 2019 | 33 | 0.140 |
Why?
| | Neoplasm Invasiveness | 1 | 2020 | 508 | 0.140 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2021 | 220 | 0.140 |
Why?
| | STAT3 Transcription Factor | 1 | 2020 | 206 | 0.140 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2020 | 70 | 0.140 |
Why?
| | Survival Rate | 2 | 2021 | 2094 | 0.140 |
Why?
| | Adrenocortical Carcinoma | 1 | 2020 | 72 | 0.140 |
Why?
| | Radiosurgery | 1 | 2022 | 399 | 0.140 |
Why?
| | Cell Communication | 1 | 2020 | 328 | 0.140 |
Why?
| | T-Lymphocytes, Regulatory | 3 | 2020 | 411 | 0.140 |
Why?
| | Interferon-alpha | 1 | 2019 | 193 | 0.140 |
Why?
| | Isoxazoles | 1 | 2018 | 56 | 0.140 |
Why?
| | Papillomavirus Infections | 1 | 2022 | 344 | 0.140 |
Why?
| | Multiple Sclerosis | 1 | 2024 | 489 | 0.140 |
Why?
| | Autoantigens | 1 | 2021 | 427 | 0.140 |
Why?
| | Ipilimumab | 1 | 2018 | 40 | 0.140 |
Why?
| | Mice, Transgenic | 3 | 2024 | 2191 | 0.130 |
Why?
| | Immunophenotyping | 3 | 2017 | 322 | 0.130 |
Why?
| | Biomarkers, Tumor | 2 | 2022 | 1329 | 0.130 |
Why?
| | Antigens, CD19 | 1 | 2018 | 128 | 0.130 |
Why?
| | Metabolome | 1 | 2021 | 391 | 0.130 |
Why?
| | Colonic Neoplasms | 2 | 2012 | 258 | 0.130 |
Why?
| | Drug Discovery | 1 | 2018 | 153 | 0.130 |
Why?
| | Head and Neck Neoplasms | 1 | 2022 | 561 | 0.130 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2018 | 124 | 0.130 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1270 | 0.130 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2019 | 218 | 0.130 |
Why?
| | Adult | 9 | 2025 | 40867 | 0.130 |
Why?
| | Oxidation-Reduction | 1 | 2020 | 1068 | 0.120 |
Why?
| | Problem-Based Learning | 1 | 2017 | 97 | 0.120 |
Why?
| | Spodoptera | 2 | 2021 | 40 | 0.120 |
Why?
| | Students, Pharmacy | 1 | 2017 | 96 | 0.120 |
Why?
| | Cell Count | 1 | 2017 | 319 | 0.120 |
Why?
| | Adipose Tissue | 1 | 2020 | 645 | 0.120 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2019 | 218 | 0.120 |
Why?
| | Algorithms | 1 | 2023 | 1850 | 0.110 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2020 | 224 | 0.110 |
Why?
| | Signal Transduction | 4 | 2024 | 5223 | 0.110 |
Why?
| | Aged | 7 | 2025 | 26212 | 0.110 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 297 | 0.110 |
Why?
| | Multiple Myeloma | 1 | 2018 | 309 | 0.110 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2021 | 1150 | 0.110 |
Why?
| | Immunotherapy, Adoptive | 1 | 2018 | 342 | 0.110 |
Why?
| | Perception | 1 | 2017 | 378 | 0.110 |
Why?
| | Tumor Cells, Cultured | 3 | 2021 | 887 | 0.110 |
Why?
| | Membrane Proteins | 1 | 2021 | 1166 | 0.100 |
Why?
| | Skin Neoplasms | 1 | 2021 | 852 | 0.100 |
Why?
| | Mice, Nude | 3 | 2020 | 680 | 0.100 |
Why?
| | Liver Neoplasms | 1 | 2020 | 777 | 0.100 |
Why?
| | Blood Cell Count | 1 | 2013 | 55 | 0.100 |
Why?
| | Prostatic Neoplasms | 1 | 2020 | 981 | 0.100 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2013 | 88 | 0.100 |
Why?
| | Arthritis, Rheumatoid | 1 | 2022 | 1180 | 0.090 |
Why?
| | Immunohistochemistry | 3 | 2022 | 1723 | 0.090 |
Why?
| | Interferon-gamma | 2 | 2021 | 784 | 0.090 |
Why?
| | Male | 12 | 2025 | 72992 | 0.090 |
Why?
| | Apoptosis | 4 | 2024 | 2443 | 0.090 |
Why?
| | Down Syndrome | 1 | 2019 | 525 | 0.090 |
Why?
| | Young Adult | 3 | 2021 | 14250 | 0.090 |
Why?
| | Suppressor Factors, Immunologic | 1 | 2011 | 4 | 0.090 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2012 | 174 | 0.090 |
Why?
| | Cells, Cultured | 2 | 2017 | 4151 | 0.090 |
Why?
| | Datasets as Topic | 2 | 2022 | 118 | 0.080 |
Why?
| | B7-H1 Antigen | 2 | 2024 | 244 | 0.080 |
Why?
| | Follow-Up Studies | 1 | 2020 | 5428 | 0.080 |
Why?
| | Neoplasm Proteins | 1 | 2013 | 442 | 0.080 |
Why?
| | Transcription Factors | 1 | 2018 | 1736 | 0.080 |
Why?
| | Curriculum | 1 | 2017 | 1074 | 0.080 |
Why?
| | Immunodominant Epitopes | 1 | 2010 | 27 | 0.080 |
Why?
| | Biomarkers | 4 | 2024 | 4302 | 0.080 |
Why?
| | Neoplasm Staging | 1 | 2013 | 1474 | 0.070 |
Why?
| | Genes, MHC Class I | 1 | 2009 | 37 | 0.070 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2025 | 1450 | 0.070 |
Why?
| | Genetic Engineering | 1 | 2009 | 88 | 0.070 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2010 | 202 | 0.070 |
Why?
| | Cell Survival | 2 | 2024 | 1103 | 0.070 |
Why?
| | Complement System Proteins | 2 | 2022 | 314 | 0.070 |
Why?
| | Histocompatibility Antigen H-2D | 1 | 2008 | 20 | 0.070 |
Why?
| | Cross-Priming | 1 | 2008 | 16 | 0.070 |
Why?
| | CD11c Antigen | 1 | 2008 | 40 | 0.070 |
Why?
| | Adjuvants, Immunologic | 1 | 2009 | 244 | 0.060 |
Why?
| | Neutrophils | 2 | 2026 | 1125 | 0.060 |
Why?
| | Molecular Targeted Therapy | 2 | 2020 | 440 | 0.060 |
Why?
| | RNA, Messenger | 3 | 2024 | 2805 | 0.060 |
Why?
| | Bacterial Load | 1 | 2026 | 67 | 0.060 |
Why?
| | Cell Culture Techniques | 1 | 2009 | 375 | 0.060 |
Why?
| | Mice, Inbred C3H | 1 | 2026 | 254 | 0.060 |
Why?
| | Phenylurea Compounds | 1 | 2026 | 119 | 0.060 |
Why?
| | Nephrocalcinosis | 1 | 2025 | 12 | 0.060 |
Why?
| | Gene Expression | 2 | 2022 | 1478 | 0.060 |
Why?
| | Aged, 80 and over | 2 | 2020 | 8346 | 0.060 |
Why?
| | Microsatellite Instability | 1 | 2025 | 55 | 0.060 |
Why?
| | Immune Tolerance | 1 | 2008 | 385 | 0.060 |
Why?
| | Cetuximab | 1 | 2025 | 111 | 0.060 |
Why?
| | Adolescent | 2 | 2025 | 22569 | 0.060 |
Why?
| | Drug Synergism | 1 | 2025 | 354 | 0.050 |
Why?
| | Ligands | 2 | 2022 | 668 | 0.050 |
Why?
| | Cisplatin | 1 | 2026 | 345 | 0.050 |
Why?
| | Cancer-Associated Fibroblasts | 1 | 2024 | 23 | 0.050 |
Why?
| | Cell Line | 1 | 2010 | 2823 | 0.050 |
Why?
| | Histocompatibility Antigens | 1 | 2024 | 102 | 0.050 |
Why?
| | Neuroendocrine Cells | 1 | 2024 | 33 | 0.050 |
Why?
| | Microsatellite Repeats | 1 | 2024 | 157 | 0.050 |
Why?
| | Neoplasm Grading | 1 | 2024 | 311 | 0.050 |
Why?
| | Wnt Signaling Pathway | 1 | 2025 | 212 | 0.050 |
Why?
| | Cell Differentiation | 1 | 2011 | 2051 | 0.050 |
Why?
| | Kynurenine | 1 | 2024 | 114 | 0.050 |
Why?
| | Recombinant Fusion Proteins | 1 | 2025 | 666 | 0.050 |
Why?
| | Imidazoles | 1 | 2024 | 247 | 0.050 |
Why?
| | Tryptophan | 1 | 2024 | 182 | 0.050 |
Why?
| | Neuroendocrine Tumors | 1 | 2024 | 119 | 0.050 |
Why?
| | Mice, Inbred C57BL | 3 | 2021 | 5992 | 0.050 |
Why?
| | Desmin | 1 | 2002 | 24 | 0.040 |
Why?
| | Myofibrils | 1 | 2002 | 49 | 0.040 |
Why?
| | Sf9 Cells | 1 | 2021 | 11 | 0.040 |
Why?
| | Lymphocytes | 2 | 2020 | 376 | 0.040 |
Why?
| | Autophagy | 1 | 2024 | 291 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2022 | 335 | 0.040 |
Why?
| | Hypoalbuminemia | 1 | 2021 | 27 | 0.040 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2021 | 78 | 0.040 |
Why?
| | Access to Information | 1 | 2021 | 48 | 0.040 |
Why?
| | Ranolazine | 1 | 2020 | 23 | 0.040 |
Why?
| | Animals, Genetically Modified | 1 | 2002 | 247 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2022 | 228 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2022 | 501 | 0.040 |
Why?
| | Seroepidemiologic Studies | 1 | 2021 | 171 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2024 | 821 | 0.040 |
Why?
| | Data Mining | 1 | 2021 | 113 | 0.040 |
Why?
| | Receptors, CCR | 1 | 2020 | 6 | 0.040 |
Why?
| | Cytokines | 3 | 2018 | 2069 | 0.040 |
Why?
| | Platelet Count | 1 | 2020 | 94 | 0.040 |
Why?
| | RNA, Viral | 1 | 2024 | 692 | 0.040 |
Why?
| | Basophils | 1 | 2020 | 52 | 0.040 |
Why?
| | Lymphocyte Subsets | 1 | 2020 | 78 | 0.040 |
Why?
| | Hematopoiesis | 1 | 2021 | 193 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2024 | 779 | 0.040 |
Why?
| | Tumor Burden | 1 | 2020 | 325 | 0.040 |
Why?
| | Leukocyte Count | 1 | 2020 | 318 | 0.040 |
Why?
| | Mutation | 1 | 2010 | 4090 | 0.040 |
Why?
| | Autoimmunity | 1 | 2025 | 933 | 0.040 |
Why?
| | Swine | 1 | 2002 | 826 | 0.040 |
Why?
| | Pancreaticoduodenectomy | 1 | 2020 | 137 | 0.040 |
Why?
| | Postoperative Period | 1 | 2020 | 351 | 0.040 |
Why?
| | Biological Availability | 1 | 2018 | 145 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2003 | 892 | 0.030 |
Why?
| | Automation | 1 | 2018 | 104 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 334 | 0.030 |
Why?
| | Radiotherapy | 1 | 2019 | 206 | 0.030 |
Why?
| | Killer Cells, Natural | 1 | 2021 | 481 | 0.030 |
Why?
| | Complement Activation | 1 | 2021 | 399 | 0.030 |
Why?
| | Structure-Activity Relationship | 1 | 2018 | 563 | 0.030 |
Why?
| | Kidney | 1 | 2025 | 1498 | 0.030 |
Why?
| | Inpatients | 1 | 2022 | 553 | 0.030 |
Why?
| | Molecular Structure | 1 | 2018 | 487 | 0.030 |
Why?
| | B-Lymphocytes | 1 | 2003 | 872 | 0.030 |
Why?
| | Lipid Metabolism | 1 | 2020 | 529 | 0.030 |
Why?
| | Aging | 1 | 2008 | 1973 | 0.030 |
Why?
| | Protein Domains | 1 | 2018 | 311 | 0.030 |
Why?
| | Homeostasis | 1 | 2021 | 644 | 0.030 |
Why?
| | Drug Delivery Systems | 1 | 2020 | 381 | 0.030 |
Why?
| | Cell Movement | 1 | 2021 | 961 | 0.030 |
Why?
| | Administration, Oral | 1 | 2018 | 867 | 0.030 |
Why?
| | Comorbidity | 1 | 2021 | 1662 | 0.030 |
Why?
| | Education, Pharmacy | 1 | 2017 | 120 | 0.030 |
Why?
| | Metabolomics | 1 | 2021 | 733 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1505 | 0.030 |
Why?
| | Educational Measurement | 1 | 2017 | 326 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 2028 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2022 | 2933 | 0.030 |
Why?
| | Program Evaluation | 1 | 2017 | 943 | 0.020 |
Why?
| | Lung | 1 | 2026 | 4116 | 0.020 |
Why?
| | Cross Reactions | 1 | 2012 | 130 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2024 | 2219 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2021 | 17322 | 0.020 |
Why?
| | Muscle, Skeletal | 1 | 2002 | 1791 | 0.020 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2011 | 56 | 0.020 |
Why?
| | Culture Media, Conditioned | 1 | 2011 | 112 | 0.020 |
Why?
| | Endocytosis | 1 | 2011 | 168 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 849 | 0.020 |
Why?
| | Hospitalization | 1 | 2021 | 2460 | 0.020 |
Why?
| | Universities | 1 | 2013 | 445 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2011 | 1049 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2024 | 11793 | 0.020 |
Why?
| | Prospective Studies | 1 | 2021 | 8075 | 0.020 |
Why?
| | Mice, Knockout | 2 | 2008 | 3130 | 0.020 |
Why?
| | Enterotoxins | 1 | 2006 | 89 | 0.010 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2006 | 177 | 0.010 |
Why?
| | DNA Primers | 1 | 2006 | 505 | 0.010 |
Why?
| | Drug Design | 1 | 2006 | 175 | 0.010 |
Why?
| | Antigen Presentation | 1 | 2006 | 208 | 0.010 |
Why?
| | Blood Cells | 1 | 2003 | 38 | 0.010 |
Why?
| | CD40 Ligand | 1 | 2003 | 40 | 0.010 |
Why?
| | Colorado | 1 | 2013 | 4556 | 0.010 |
Why?
| | Coculture Techniques | 1 | 2003 | 247 | 0.010 |
Why?
| | Toes | 1 | 2002 | 16 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2006 | 2131 | 0.010 |
Why?
| | Sarcomeres | 1 | 2002 | 97 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2006 | 2883 | 0.010 |
Why?
| | Antibody Formation | 1 | 2003 | 288 | 0.010 |
Why?
| | Child | 1 | 2021 | 22738 | 0.010 |
Why?
| | Microscopy, Electron | 1 | 2002 | 414 | 0.010 |
Why?
| | Immunoglobulins | 1 | 2002 | 163 | 0.010 |
Why?
| | Organ Size | 1 | 2002 | 461 | 0.010 |
Why?
| | Cattle | 1 | 2003 | 946 | 0.010 |
Why?
| | Echocardiography | 1 | 2002 | 648 | 0.010 |
Why?
| | Birth Weight | 1 | 2002 | 517 | 0.010 |
Why?
| | Biomechanical Phenomena | 1 | 2002 | 860 | 0.010 |
Why?
| | Placenta | 1 | 2002 | 787 | 0.010 |
Why?
| | Phenotype | 1 | 2002 | 3170 | 0.010 |
Why?
|
|
Jordan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|